EUVIMEDEUVIMED entdecken
Crossref

M1C mediates LINE-1 transcription in PARP inhibitor-treated prostate cancer cells

Keisuke Shigeta, Shinkichi Takamori, Hiroki Ozawa, Naoki Haratake, Mai Onishi, Tatsuaki Daimon, Tomohiro Kitano, Atrayee Bhattacharya, Atsushi Fushimi, Mototsugu Oya, Mark D Long, Donald Kufe

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218320 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Keisuke Shigeta und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Urology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Piperazines, Prostatic Neoplasms, Castration-Resistant, Phthalazines. Die Arbeit nennt 85 Literaturangaben. Gefördert von: Mitsukoshi Health and Welfare Foundation, National Institutes of Health, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced castration-resistant prostate cancer (CRPC) is responsive to PARP inhibitors, but only in settings of defects in homologous recombination (HR). The oncogenic M1C protein drives CRPC progression; however, it is not known if M1C plays a role in the response to PARP inhibition. The present work demonstrates that M1C is induced by olaparib treatment of HR-competent CRPC cells. As a result, M1C drives (i) ATM expression, (ii) phosphorylation of KAP1(S824) and (iii) activation of STING, which have been linked to derepression of the LINE-1 (L1) retrotransposon. In this way, M1C is necessary for induction of (i) L1-5'UTR, L1-ORF1 and L1-ORF2 transcripts and (ii) the encoded ORF1p RNA binding protein. Activation of retrotransposons induces genomic instability and drug resistance. By extension, we show that M1C also activates HERV-K102/108 gag, pol and env genes and expression of the HERV-K ENV protein. Our work further demonstrates that M1C integrates L1 and HERV-K activation with induction of APOBEC3 (A3) genes that evolved to restrain genomic instability induced by these retrotransposons. Of translational relevance, these findings demonstrate that M1C (i) is essential for inducing L1, HERV-K and A3 expression and resistance of CRPC cells to olaparib, and (ii) is a target for advancing the treatment of HR-competent CRPC with PARP inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsPiperazinesProstatic Neoplasms, Castration-ResistantPhthalazinesLong Interspersed Nucleotide ElementsHumansMaleCell Line, TumorGene Expression Regulation, NeoplasticTranscription, GeneticDrug Resistance, Neoplasm

Stichwörter der Autor:innen

APOBEC3Castration-resistant prostate cancerHERV-KHomologous recombinationLINE-1M1COlaparibRetrotransposons

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPiperazinesolaparibPhthalazines

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Donald_Kufe@dfci.harvard.edu.

Förderung

  • Mitsukoshi Health and Welfare Foundation
  • National Institutes of Health
  • Japan Society for the Promotion of Science
  • National Cancer Institute
  • Dana-Farber Cancer Institute

Zitieren

APA

Shigeta, K., Takamori, S., Ozawa, H., Haratake, N., Onishi, M., Daimon, T., Kitano, T., Bhattacharya, A., Fushimi, A., Oya, M., Long, M. D., & Kufe, D. (2026). M1C mediates LINE-1 transcription in PARP inhibitor-treated prostate cancer cells. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218320

Vancouver

Shigeta K, Takamori S, Ozawa H, Haratake N, Onishi M, Daimon T, et al. M1C mediates LINE-1 transcription in PARP inhibitor-treated prostate cancer cells. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218320

BibTeX
@article{Shigeta2026,
  author = {Shigeta, Keisuke and Takamori, Shinkichi and Ozawa, Hiroki and Haratake, Naoki and Onishi, Mai and Daimon, Tatsuaki and Kitano, Tomohiro and Bhattacharya, Atrayee and Fushimi, Atsushi and Oya, Mototsugu and Long, Mark D and Kufe, Donald},
  title = {M1C mediates LINE-1 transcription in PARP inhibitor-treated prostate cancer cells},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218320}
}
Kostenlos starten →